Exelixis
EXEL
#1316
Rank
$17.25 B
Marketcap
$70.70
Share price
0.17%
Change (1 day)
64.50%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2026 (TTM): $3.46

According to Exelixis's latest financial reports the company's current EPS (TTM) is $3.46. In 2025 the company made an earnings per share (EPS) of $2.89.

EPS history for Exelixis from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)$3.4619.72%
2025$2.89
2023$0.6514.61%
2022$0.57-22.97%
2021$0.74100%
2020$0.37-65.09%
2019$1.06-53.91%
2018$2.30333.96%
2017$0.53-260.61%
2016-$0.33-58.75%
2015-$0.80-42.45%
2014-$1.395.3%
2013-$1.32

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
$6.68 93.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
$0.71-79.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
$17.38 402.31%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
$1.98-42.76%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
$0.99-71.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
$4.52 30.64%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
$2.88-16.84%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-$14.22-510.98%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-$0.84-124.28%๐Ÿ‡บ๐Ÿ‡ธ USA